Cytomegalovirus Infections clinical trials
The registry lists 370 studies for Cytomegalovirus Infections across more than 10 countries. 57 are recruiting or about to start. 274 of them are mainly about Cytomegalovirus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its narrower condition Cytomegalovirus Retinitis too: 402 studies, 58 open.
Get an email when these change. Save the Cytomegalovirus Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (42) · Hoffmann-La Roche (19) · Assistance Publique - Hôpitaux de Paris (12) · National Heart, Lung, and Blood Institute (NHLBI) (10) · City of Hope Medical Center (9) · ModernaTX, Inc. (8) · Merck Sharp & Dohme LLC (6) · Astra USA (6)
What is being tested here
Drugs under test in Cytomegalovirus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here mTOR inhibitors 1 open · Reverse transcriptase inhibitors 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Aug 2027Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients · Phase 3 · University of Wisconsin, Madison
- Sep 2027Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections · Phase 3 · Assistance Publique - Hôpitaux de Paris
- Dec 2026Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation · University Hospital, Bordeaux
- Dec 2026A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® · University Hospital, Basel, Switzerland
- Dec 2026Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant · City of Hope Medical Center
- Dec 2026Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients · University of Pennsylvania
- Dec 2026Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) · New York Medical College
- Jan 2027Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant Study · Susanne Dam Nielsen, MD, DMSc
- Jan 2027CMV Refractory and Resistant Infection in Solid Organ Transplant Recipients in Argentina · Hospital Italiano de Buenos Aires
- Feb 2027ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse · Wits Health Consortium (Pty) Ltd
Who these studies take
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger. 19 (54%) take children under 18. 1 (3%) are for women only and 0 (0%) for men only; 2 (6%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 15 (43%) | 15 (43%) |
| 18 | 30 (86%) | 29 (83%) |
| 30 | 26 (74%) | 25 (71%) |
| 40 | 25 (71%) | 24 (69%) |
| 50 | 25 (71%) | 24 (69%) |
| 65 | 25 (71%) | 24 (69%) |
| 75 | 22 (63%) | 21 (60%) |
| 85 | 21 (60%) | 20 (57%) |
Across all 370 studies, recruiting or not: 40% stop at 75 or younger and 34% at 65; 46% take children; 9% are for women only and 3% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Cytomegalovirus Infections studies take
Of 29 phase 2 interventional studies under Cytomegalovirus Infections, half reached primary completion within 44 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 28 mo16–45 · 21 studies | — | — |
| Phase 2 | 44 mo35–62 · 29 studies | — | — |
| Interventional, no phase | 40 mo24–56 · 23 studies | — | — |
| Observational | 45 mo34–61 · 30 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 370. Browse all 370 → or search them.
- Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)RecruitingNCT03266640Phase 21 country
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell TransplantRecruitingNCT03354728Phase 1/21 country
- TETRAVI Expanded Access ProgramAvailableNCT07104591
- Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC AloneRecruitingNCT07225972Phase 31 country
- CMV Refractory and Resistant Infection in Solid Organ Transplant Recipients in ArgentinaNot yet recruitingNCT077877671 country
- Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and IINot yet recruitingNCT07513623Phase 23 countries
- CytoGam for CMV Infection or Disease in Solid Organ Transplant RecipientsEnrolling by invitationNCT07009548Phase 41 country
- Study Evaluating the Efficacy and Safety of ArtesunateRecruitingNCT06853184Phase 22 countries
- R-MVST Cells for Treatment of Viral Infections in Children and Young AdultsRecruitingNCT06926894Phase 11 country
- CMV-CMI in csCMVi After HSCTRecruitingNCT076887591 country
- Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.RecruitingNCT07685457Not applicable1 country
- Anti-viral T-cell Therapy by Gamma CaptureEnrolling by invitationNCT06027879Phase 1/21 country
- Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.RecruitingNCT07670468Phase 1/21 country
- Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT PatientsRecruitingNCT052347239 countries
- Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant RecipientsRecruitingNCT06407232Phase 31 country
- R-MVST Cells for Treatment of Viral InfectionsRecruitingNCT05183490Phase 11 country
- Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus InfectionRecruitingNCT076353681 country
- Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health ProfessionalsRecruitingNCT066944281 country
- Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.RecruitingNCT07569653Phase 41 country
- Letermovir vs Valganciclovir in CMV R+ Kidney TransplantNot yet recruitingNCT07571135Phase 41 country
- HORUS-Cytomegalovirus Open Proof-of-concept Exploratory TrialNot yet recruitingNCT07570433Phase 43 countries
- Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT069161951 country
- Renal Ex Vivo SYN002 Perfusion to Eliminate CMV TransmissionNot yet recruitingNCT07488481Early Phase 11 country
- Breakthrough CMV Lung Transplant -MulticentreRecruitingNCT044399161 country
- Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused by Congenital Cytomegalovirus InfectionNot yet recruitingNCT07450365Phase 4
- Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis DurationNot yet recruitingNCT07443501
- ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAseNot yet recruitingNCT07379203Phase 2
- Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCTRecruitingNCT06812598Not applicable1 country
- Overview of Targeted Screening for Congenital Infection Guided by Neonatal Hearing ScreeningRecruitingNCT073358741 country
- Letermovir-based Dual Therapy for Treatment of Cytomegalovirus InfectionsRecruitingNCT06334497Phase 31 country
- Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot StudyRecruitingNCT07294547Not applicable1 country
- T Cell Therapy of Opportunistic Cytomegalovirus InfectionRecruitingNCT02982902Early Phase 11 country
- HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCRNot yet recruitingNCT07210242
- CMV-associated Immunomodulation in Renal Transplant PatientsNot yet recruitingNCT06976008Not applicable1 country
- A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus InfectionNot yet recruitingNCT071410951 country
- Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised ImmunityRecruitingNCT06909110Phase 1/21 country
- Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV InfectionsRecruitingNCT04832607Phase 36 countries
- Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT070133701 country
- Long-Term Outcomes of Children With Congenital CMV in New York StateRecruitingNCT062265581 country
- QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative ColitisRecruitingNCT04030676Not applicable1 country
- A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®RecruitingNCT02007356Phase 21 country
- ATG Individualized Dosing Model in URD-PBSCT.RecruitingNCT06572462Phase 21 country
- HCMV Breakthrough Infections During Letermovir ProphylaxisRecruitingNCT06339892Not applicable1 country
- Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)RecruitingNCT06341543Not applicable1 country
- Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study AnalysisRecruitingNCT060588581 country
- Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBTRecruitingNCT064416691 country
- The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based RegimenNot yet recruitingNCT06362720
- Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus InfectionNot yet recruitingNCT06341686Phase 3
- Congenital CYtoMEgalovirus Infection in VIEtnam (CYMEVIE)RecruitingNCT048221421 country
- Real-world CMV Outcomes Among Kidney Transplant Recipients in BrazilEnrolling by invitationNCT062632181 country